ERBB2 and breast cancer: This is primarily due to the unique pathophysiological characteristics of the tumor microenvironment in HR+/HER2- BC, which is characterized by low levels of TILs, reduced expression of HLA class I molecules (123), and the recruitment of immunosuppressive cells such as macrophages and regulatory T cells (Tregs).